Autosomal Recessive Nonsyndromic Hearing Loss 93
Disease Details
Family Health Simplified
- Description
- Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) is a genetic disorder characterized by sensorineural hearing loss without other associated clinical abnormalities.
- Type
-
Autosomal recessive nonsyndromic hearing loss 93 (DFNB93)
Type of genetic transmission: Autosomal recessive - Signs And Symptoms
-
Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) primarily manifests as early-onset sensorineural hearing loss.
**Signs and Symptoms:**
- Sensorineural hearing loss detected in infancy or early childhood
- Generally bilateral and can range in severity from mild to profound
- Hearing loss is typically stable and non-progressive over time
- No associated syndromic features (e.g., no abnormalities in other parts of the body, such as vision, balance, or cognitive function)
This type of hearing loss is due to genetic mutations inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations.
**nan:** Information about "nan" is not provided within the typical context of autosomal recessive nonsyndromic hearing loss 93. Please clarify or provide additional context if needed. - Prognosis
- Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) is a form of inherited hearing impairment. The prognosis for individuals with ARNSHL93 varies depending on the specific genetic mutations involved and the severity of the hearing loss. Generally, hearing loss in this condition is sensorineural and typically present from birth. The degree of hearing impairment can range from mild to profound. While there is currently no cure, early diagnosis and intervention, such as the use of hearing aids or cochlear implants, along with speech therapy, can significantly improve quality of life and communication abilities.
- Onset
- Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) typically has an onset at birth or prelingual, meaning it is present before the development of speech and language skills.
- Prevalence
- The prevalence of autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) is not well-documented, and specific prevalence data are not readily available. It's considered a rare genetic disorder, typically identified in cases with a known family history or through genetic testing.
- Epidemiology
- Autosomal recessive nonsyndromic hearing loss 93 (DFNB93) is a rare genetic condition characterized by hearing loss that is not associated with other symptoms. The prevalence and distribution of DFNB93 are not well-documented, as it is a rare subtype of inherited hearing loss. Epidemiological data are limited, making it difficult to provide detailed information on its occurrence within the general population.
- Intractability
- Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) is a genetic condition characterized by hearing loss without other associated clinical symptoms. The intractability of this condition depends on several factors, including the specific genetic mutation involved, the degree of hearing loss, and the timing of intervention. While the genetic basis of the disease itself cannot be cured, various intervention strategies such as hearing aids, cochlear implants, and other assistive devices can significantly improve the quality of life for affected individuals. Early detection and intervention are crucial for optimizing outcomes. Therefore, while the underlying genetic condition is not curable, effective management options are available.
- Disease Severity
- Autosomal recessive nonsyndromic hearing loss 93 (DFNB93) typically manifests as prelingual, severe to profound hearing loss. The severity can vary, but affected individuals generally experience significant hearing impairment from an early age.
- Pathophysiology
- Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) is caused by mutations in the CIB2 gene. The CIB2 gene encodes a calcium- and integrin-binding protein. Mutations in this gene disrupt normal inner ear function, particularly affecting hair cells in the cochlea, which are essential for converting sound vibrations into neural signals. This disruption leads to hearing impairment independent of other syndromic features.
- Carrier Status
-
Autosomal Recessive Nonsyndromic Hearing Loss 93 (DFNB93) is a type of genetic hearing loss. Individuals who are carriers of this condition have one mutated copy of the gene but do not typically exhibit symptoms. If both parents are carriers, there is a 25% chance with each pregnancy that their child will inherit two mutated copies, leading to the condition. Carriers themselves do not usually experience the hearing loss associated with DFNB93.
"nan" may refer to something specific outside the context provided but is not applicable here. - Mechanism
-
Autosomal recessive nonsyndromic hearing loss 93 (DFNB93) is a genetic condition characterized by hearing loss that is inherited in an autosomal recessive manner and does not involve other syndromic features. The condition is caused by mutations in the CLRN2 gene.
**Mechanism:**
The CLRN2 gene provides instructions for making a protein called clarin-2. Clarin-2 is involved in the normal function and maintenance of hair cells in the inner ear, which are essential for hearing.
**Molecular Mechanisms:**
Mutations in the CLRN2 gene lead to the production of an abnormal clarin-2 protein. This defective protein disrupts the functioning and maintenance of hair cells in the cochlea, which impairs the ability to convert sound waves into electrical signals that the brain can interpret, resulting in hearing loss. The exact nature of the mutations can vary, involving missense mutations, nonsense mutations, or deletions, all of which compromise protein function.
Therefore, DFNB93 is primarily a result of compromised clarin-2 function due to genetic mutations in the CLRN2 gene, leading to a loss of hair cell integrity and subsequent hearing loss. - Treatment
-
For autosomal recessive nonsyndromic hearing loss 93 (ARNSHL 93), there is currently no cure. Treatment primarily focuses on managing hearing loss and improving the quality of life. Options may include:
1. **Hearing Aids**: Devices to amplify sound for those with residual hearing.
2. **Cochlear Implants**: For individuals with severe to profound hearing loss, these devices can provide a sense of sound.
3. **Assistive Listening Devices**: Tools like FM systems to help in specific settings.
4. **Speech Therapy**: To improve communication skills.
5. **Educational Support**: Specialized programs in schools to support learning.
Regular follow-ups with audiologists and ENT specialists are essential for optimal management. - Compassionate Use Treatment
-
Autosomal recessive nonsyndromic hearing loss 93 (DFNB93) is a genetic condition causing hearing impairment without other associated symptoms. For compassionate use treatments or experimental options:
1. **Gene Therapy**: Research is ongoing to develop gene therapies that target the specific genetic mutations responsible for DFNB93.
2. **CRISPR/Cas9**: Experimental use of this gene-editing tool offers potential for correcting genetic mutations at their source.
3. **Stem Cell Therapy**: Exploring the use of stem cells to regenerate or repair damaged cochlear cells.
4. **Pharmacological Approaches**: Investigational drugs aiming to protect or restore auditory function.
5. **Cochlear Implants and Hearing Aids**: While not experimental, these devices are commonly used to manage hearing loss symptoms and may be part of a comprehensive treatment plan.
These experimental treatments are in various stages of research and development, and their availability may be limited to clinical trials. - Lifestyle Recommendations
-
For individuals with autosomal recessive nonsyndromic hearing loss 93 (ARNSHL 93), lifestyle recommendations focus on enhancing communication and maximizing quality of life:
1. **Hearing Aids/Cochlear Implants:** Consult with an audiologist to determine the best hearing devices to improve auditory perception.
2. **Educational Support:** Enroll in specialized education programs that include speech therapy and possibly sign language education.
3. **Regular Check-ups:** Regular visits to an audiologist and otolaryngologist for monitoring and managing hearing health.
4. **Protective Measures:** Use ear protection in noisy environments to prevent additional hearing damage.
5. **Healthy Environment:** Create a supportive home and work environment with visual alarms and listening aids.
6. **Communication Training:** Engage in communication strategies, such as lip-reading classes, and use assistive technologies like captioning services.
7. **Support Systems:** Join support groups or seek counseling to address the emotional and social aspects of living with hearing loss.
Adapting these strategies can significantly improve daily life and enable better communication for individuals with ARNSHL 93. - Medication
- There is no specific medication to treat autosomal recessive nonsyndromic hearing loss 93 (ARNSHL 93). Management typically focuses on hearing aids, cochlear implants, and other supportive therapies to improve hearing and communication abilities. Genetic counseling is also recommended for affected individuals and their families.
- Repurposable Drugs
- Currently, there are no widely recognized repurposable drugs specifically for Autosomal Recessive Nonsyndromic Hearing Loss 93 (ARNSHL93). Given the genetic basis of this condition, which involves mutations typically in a single gene affecting hearing, treatment strategies are more likely to focus on genetic or auditory support interventions rather than repurposing existing drugs. However, research is ongoing and new therapeutic avenues may emerge. For the most accurate and personalized treatment options, consulting a healthcare provider or a specialist in genetic hearing loss is recommended.
- Metabolites
- For autosomal recessive nonsyndromic hearing loss 93 (ARNSHL 93), there is no specific information linking it to particular metabolic abnormalities or alterations in metabolite levels. This genetic condition primarily affects hearing without broader systemic involvement, so metabolites are not typically relevant in its diagnosis or understanding.
- Nutraceuticals
- There are no specific nutraceuticals recommended or proven effective for treating autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93). Treatment typically focuses on hearing aids, cochlear implants, and other supportive interventions. Consult with healthcare providers for personalized advice and options.
- Peptides
- Autosomal recessive nonsyndromic hearing loss 93 (ARNSHL93) is characterized by isolated hearing loss without other associated symptoms. It is associated with mutations in the COL11A1 gene. The specific peptides or proteins directly related to this condition are not well-documented. The term "nan" does not provide relevant information in this context. Please specify if you require detailed information on a specific aspect.